Aim: We aimed to determine the glypican-3 levels in patients diagnosed with COVID-19, compare these values with the healthy controls, and analyze the evaluation of glypican-3 levels with inflammatory markers, including interleukin-6 (IL-6), to determine its role in disease pathogenesis.

Material and Methods: A total of 88 participants (58 patients and 30 controls) were included. Medical history and laboratory findings of the population were recorded. Serum glypican-3 and IL-6 levels were analyzed by the Enzyme-linked immunosorbent assay method.

Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH) levels, and IL-6 levels were significantly higher in the COVID-19 patient group than the healthy controls, while glypican-3 levels were significantly lower in the patient group (p<0.001). Glypican-3 levels significantly and inversely correlated with serum AST, CRP, ferritin, IL-6, and LDH levels (p<0.05).

Conclusions: We found that the levels of glypican-3 decreased in COVID-19 patients. Additionally, serum glypican-3 levels are inversely correlated with CRP and IL-6 levels. Targeting glypican-3 may be useful in understanding the pathophysiology of COVID-19.